Acid maltase deficiency
Natural Standard Monograph, Copyright © 2013 (www.naturalstandard.com). Commercial distribution prohibited. This monograph is intended for informational purposes only, and should not be interpreted as specific medical advice. You should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.
Acid alpha-glucosidase, acid maltase enzyme, AMD, GAA, glycogen, glycogen storage disease type II, glycogenosis type II, lysosomal storage disease, muscle disorder, muscles, Pompe disease.
Acid maltase deficiency (AMD), also known as Pompe disease, is a genetically inherited disease that affects muscle function. Inherited diseases are passed on from parents to a child. Patients with AMD have a defect, or mutation, in a gene that functions in muscles, called the acid alpha-glucosidase (GAA) gene. This genetic mutation causes a substance called glycogen to build up in the muscles of patients with AMD. Glycogen is a form of starch that is used to store short-term energy.
Glycogen buildup in the muscles of patients with AMD causes damage to the muscles, which leads to a progressive weakening of the muscles. This glycogen buildup may weaken the muscles of the heart and respiratory system. Cardiac or respiratory failure is the most common cause of death in patients with AMD.
AMD is estimated to affect about one in 40,000 to 100,000 births. The time of onset of AMD can vary among patients and can occur in infants, children, or adults. The infant onset form is considered to be the most severe, and usually results in death within one year. In general, the later the onset of AMD, the more slowly it will progress, and the less severe the symptoms. Children and adults diagnosed with AMD usually have a life expectancy from 10 to 20 years after symptoms begin to appear.
Currently there is no known way to prevent AMD. However, a treatment called Myozyme®, which restores functional alpha-glucosidase enzyme to a patient, has been shown to be effective in treating the disease.
Acid maltase deficiency should not be confused with age-related macular degeneration, a different disease that is also abbreviated as AMD.
Acid maltase deficiency (AMD) is a recessive inherited genetic condition. Normal individuals have two copies of most genes (one inherited from the father and one from the mother). In a recessive genetic disorder, both copies of a certain gene need to be defective for the condition to manifest itself. It has been shown that mutations in the acid alpha-glucosidase gene may cause AMD. People who only have one mutated gene are called "carriers." If only one parent is a carrier, none of the children will have AMD, but 50% of the children will also be carriers; if both parents are carriers, then there is a 50% chance that a child will be a carrier and a 25% chance that a child will have AMD.
Acid maltase deficiency (AMD) is caused by mutations in a gene called acid alpha-glucosidase, or GAA. Normally, this gene makes a protein called the acid alpha-glucosidase enzyme (also called the acid maltase enzyme). In patients with AMD, these mutations cause the acid alpha-glucosidase enzyme to lose most or all of its function.
The acid alpha-glucosidase enzyme normally functions in muscle cells to break down glycogen, a form of starch that is used to store short-term energy. In people with AMD, the mutated acid alpha-glucosidase enzyme cannot carry out this function. Therefore, glycogen builds up the in the muscles of patients with AMD. This glycogen buildup leads to an expansion of the lysosome (a compartment in the muscle cell that is involved in digesting and degrading materials such as glycogen and other proteins), which may damage and impair the function of the muscle cell. In some cases, glycogen or other substances may begin leaking from the muscle cell.
Signs and Symptoms
The time of onset of acid maltase deficiency (AMD) varies among patients, and can occur in infants, children, or adults. The infant onset form is considered to be the most severe. In general, the later the onset of AMD, the more slowly it will progress, and the less severe the symptoms. This is because patients with later onset AMD may have less severe mutations in the acid alpha-glucosidase gene.
Patients with AMD have a buildup of glycogen in their muscles. This leads to a weakening of muscles that progressively worsens over time. In patients with AMD, the glycogen buildup primarily occurs in a compartment of the muscle cell called the lysosome, which is involved in digesting and degrading other materials (such as proteins) in the cell. This glycogen buildup leads to an expansion of the lysosome, which may damage and impair the function of the muscle cell. Muscles of the hips, upper legs, shoulders, upper arms, trunk, and diaphragm may all grow progressively weaker in patients with AMD.
The glycogen buildup may impair cardiac and respiratory muscles, which may lead to serious complications. Cardiac muscles are most likely to be affected in infants, and not as likely to be affected in individuals who develop the disease later in life. Hearts of infants with AMD become severely thickened and enlarged, making it more difficult to pump blood.
Infants who develop AMD may display feeding problems, poor weight gain, a lack of muscle tone, and enlarged hearts and tongues.
Patients who develop AMD as children or adults may experience fatigue, as a result of muscle weakness, and high blood pressure.
Because the onset of acid maltase deficiency (AMD) may not occur until later in life, and because many of the physical symptoms (such as fatigue or weakness) are common in other diseases, AMD can be difficult to diagnose. AMD is considered easiest to diagnose in infants, because the symptoms usually develop more rapidly.
GAA testing: One diagnostic test involves measuring the enzymatic function of the protein made by the acid alpha-glucosidase gene (GAA). This enzyme has greatly reduced (or no) activity in patients with AMD. Testing for GAA activity, which is usually performed on a tissue or blood sample, is considered to be the most conclusive way of diagnosing AMD.
Physical signs: In infants, weakness and lack of muscle tone may indicate the presence of AMD.
Heart tests: Because infants with AMD usually have heart defects, heart testing may be performed to assist in diagnosing AMD. Two commonly used heart tests are echocardiography and electrocardiography. In echocardiography, sound waves are bounced off the heart to create a visual image of the heart. This test can be used to check for enlargement or abnormal thickness of the heart, which would indicate AMD. In electrocardiography, electrodes are placed on the chest to monitor heart rhythm and heartbeat frequency. Patients with AMD often have an irregular heart rate.
Serum CK test: Tests that measure an enzyme called creatine kinase (CK) in the blood can be used to identify muscle defects. CK is an enzyme that helps carry out a chemical reaction on creatine, a substance used by the body for energy. CK levels rise in the blood in patients with AMD when muscle cells break open, but CK levels may also rise due to other factors, such as a heart attack or normal exercise. Therefore, the serum CK test may not be able to diagnose a patient specifically with AMD, because other diseases that affect the muscles, as well as normal exercise, also result in increased levels of serum CK.
Genetic testing: Mutations in the acid alpha-glucosidase gene are known to cause AMD. Genetic tests can be used to check for these mutations and diagnose AMD. These tests may be used to confirm a diagnosis if there is a family history of AMD, or if symptoms of AMD are present.
Cardiac/respiratory problems: Large amounts of glycogen may build up in the respiratory and cardiac muscles of patients with acid maltase deficiency (AMD). This can lead to respiratory and cardiac failure, and ultimately death.
In AMD onset in infants, heart and respiratory complications usually cause death by the age of one year. Hearts of infants with AMD become severely thickened and enlarged, making it more difficult to pump blood.
In AMD onset in children or adults, respiratory failure is a more common complication than cardiac failure. The respiratory muscles may become weakened, which can lead to difficulty breathing. Children and adults diagnosed with AMD usually have a life expectancy from 10 to 20 years after symptoms begin to appear.
Lung infections, such as bronchitis or pneumonia, may develop more easily in patients with AMD.
Muscle weakness can make it difficult for patients to perform everyday tasks, such as eating or walking.
Feeding tube: Some infants with AMD have difficulty feeding, so tube feeding may be used to deliver nutrients.
Ventilators: Because many patients with acid maltase deficiency (AMD) develop respiratory problems, a mechanical ventilator may be recommended by a doctor to assist with breathing. A mechanical ventilator is a machine that sends air into the lungs. In some cases, ventilators may be used just at night, and they are often used when the disease has progressed and become more severe.
Viral medications: Flu shots or other viral vaccines may help reduce the risk of infection in the lungs.
Assistive devices: Devices, such as legs braces, walkers, or wheelchairs, may be used to help patients with weakened muscles who have difficulty walking.
Enzyme therapy: An enzyme replacement therapy called Myozyme® has been approved to treat AMD. Myozyme® is a recombinant form of alpha-glucosidase, which can provide functioning enzymes to patients with AMD. This therapy reduces glycogen buildup and appears to restore muscle function. In a clinical trial, Myozyme® has been shown to increase survival in infants with AMD. Over 80% of infants taking Myozyme® were alive and free of ventilator support at two years of age. Trials testing Myozyme® in adults are ongoing.
Myozyme® requires a prescription, and is recommended at a dosage of 20 milligrams/kilogram body weight, administered every two weeks by an injection.
A number of side effects have been observed in patients taking Myozyme®, including an irregular heartbeat, swelling at the injection site, headache and dizziness, swelling of the hands or feet, and a severe allergic reaction (involving rash, hives, difficulty breathing, and tightness in the chest).
Currently, there is a lack of scientific data on the use of integrative therapies for the treatment or prevention of acid maltase deficiency.
There are currently no known ways to prevent acid maltase deficiency (AMD). However, a recently developed enzyme replacement therapy called Myozyme® may help treat the symptoms of AMD. Additionally, prenatal genetic screening may be performed to assess the risk that a child will develop AMD.
This information has been edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).
Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Acid Maltase Deficiency Association. www.amda-pompe.org.
Bijvoet AG, van de Kamp EH, Kroos MA, et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet. 1998 Jan;7(1):53-62. View Abstract
Fraites TJ Jr, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther. 2002 May;5(5 Pt 1):571-8. View Abstract
Muscular Dystrophy Association. www.mdausa.org.
Pompe Community. www.pompe.com.
Natural Standard: The Authority on Integrative Medicine. www.naturalstandard.com.
Rucker M, Fraites TJ Jr, Porvasnik SL, et al. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development. 2004 Jun;131(12):3007-19. View Abstract
Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006 Dec;86(12):1208-20. View Abstract
Umapathysivam K, Whittle AM, Ranieri E, et al. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem. 2000 Sep;46(9):1318-25. View Abstract
Copyright © 2013 Natural Standard (www.naturalstandard.com)
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.
March 22, 2017